Baillie Gifford, a prominent global investment manager, has established a new stake in Idexx Laboratories, a leader in veterinary diagnostics and software. According to its latest quarterly disclosure, the firm acquired 353,800 shares of Idexx, valued at approximately $186.25 million. This new holding represents about 0.17% of Baillie Gifford's reported portfolio.
Idexx Laboratories develops, manufactures, and distributes products and services for companion animal veterinary, livestock and poultry, and water testing markets. It's important to note that this 13F filing reflects trades made during the second quarter of 2026, which ended June 30, and was made public on August 6. The filing indicates a past position, not a real-time transaction.